tirzepatide gastroparesis case report Lawsuit Filed Against Ozempic, Mounjaro Over 'Stomach Paralysis' Understanding gastroparesis and weight loss

Removal from Category 2 does not guarantee long-term regulatory acceptance, nor does it replace the need for clinical judgment, proper sourcing, and compliance with federal and state guidelines

The net blood pressure effect depends on the SNRI dose, tirzepatide dose, and magnitude of weight loss

Both medications can cause nausea, headache, dizziness, and constipation

10.1073/pnas.80.18.5485 80 LovicD.PiperidouA.ZografouI.GrassosH.PittarasA.ManolisA

doi: 10.1021/acs.langmuir.1c01434 203 ZwierMCChongLT

STEP-UP trial success : At an escalated 7.2 mg dose, participants in clinical studies achieved 21%25% weight loss, demonstrating performance similar to Mounjaros in head-to-head evaluations